Nobel Laureate Joins NeuroNOS to Advance Autism and Alzheimer’s Drug Development

NeuroNOS, a subsidiary of Beyond Air (NASDAQ: XAIR), announced the appointment of Nobel Prize-winning chemist Professor Dan Shechtman to its Scientific Advisory Board (SAB), further strengthening its leadership in developing treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD). Professor Shechtman, who won the 2011 Nobel Prize in Chemistry for the discovery of quasicrystals, joins another Nobel laureate, Professor Roger Kornberg of Stanford University, on the SAB.

CEO Amir Avniel emphasized that the addition of Shechtman underscores NeuroNOS’s commitment to pioneering transformative therapies for complex brain disorders. The company’s proprietary platform integrates behavioral science, advanced AI, and lab-based capabilities to target the core symptoms of ASD and AD. Preclinical studies have shown promising results, and NeuroNOS is aiming to submit an Investigational New Drug (IND) application to the FDA in preparation for first-in-human clinical trials for ASD, anticipated to begin in 2026.

Professor Shechtman expressed enthusiasm about contributing to the development of life-changing therapies, highlighting the importance of scientific innovation in addressing neurological disorders that affect millions globally. Professor Haitham Amal, NeuroNOS’s CSO, noted that Shechtman’s appointment comes at a crucial time as the company advances its lead drug candidate, BA-102, through development. His expertise is expected to accelerate the translation of foundational science into real-world treatments.